Steven Norris, MD
Internal Medicine · Amarillo, TXNPI 1437186434
Payments from drug & device makers
Across 507 payments — averaging $14.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$964
- AstraZeneca$723
- Pfizer$699
- AbbVie$653
- Lilly USA, LLC$616
- GSK$593
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,26897%
- Education$2063%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 65 | $964 |
| AstraZeneca | 41 | $723 |
| Pfizer | 51 | $699 |
| AbbVie(2 entities) | 43 | $653 |
| Lilly USA, LLC | 58 | $616 |
| GSK | 48 | $593 |
| Astellas Pharma US Inc | 21 | $541 |
| Boehringer Ingelheim | 31 | $416 |
| Amgen | 23 | $346 |
| E.r. Squibb & Sons, L.L.C. | 29 | $344 |
| Amarin Pharma, Inc. | 13 | $195 |
| Phathom Pharmaceuticals, Inc. | 12 | $180 |
| Novartis | 9 | $175 |
| Sanofi-aventis U.S. LLC | 11 | $153 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $150 |
| Johnson & Johnson | 7 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $106 |
| Inspire Medical Systems, Inc. | 1 | $59 |
| Dexcom, Inc. | 3 | $57 |
| Merck | 3 | $41 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Antares Pharma, Inc. | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Acadia Pharmaceuticals Inc | 1 | $28 |
| Exact Sciences | 2 | $28 |
| Abbott | 1 | $20 |
| Medtronic | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Siemens Medical Solutions USA, Inc. | 1 | $16 |
| Viatris Specialty LLC | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $13 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$7,474 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 165 | $175,733 |
| JardianceEmpagliflozin | 101 | $96,776 |
| TrulicityDulaglutide | 86 | $86,606 |
| OzempicSemaglutide | 62 | $68,044 |
| EliquisApixaban | 70 | $67,303 |
| RybelsusSemaglutide | 36 | $63,964 |
| FarxigaDapagliflozin Propanediol | 61 | $58,842 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 57 | $47,246 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $41,603 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $24,824 |
| JanuviaSitagliptin Phosphate | 32 | $23,575 |
| Xigduo XrDapaglifloz Propaned/Metformin | 22 | $21,955 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $20,260 |
| XareltoRivaroxaban | 18 | $19,981 |
| MyrbetriqMirabegron | 16 | $19,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $616 | $262,338251 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $416 | $158,627175 claims |
| Novo NordiskOzempic, Rybelsus | $964 | $132,00898 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $723 | $92,577116 claims |
| PfizerEliquis | $699 | $67,30370 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $593 | $38,64154 claims |
| AbbVieViberzi, Linzess, Synthroid | $653 | $26,737108 claims |
| MerckJanuvia | $41 | $23,57532 claims |
| Johnson & JohnsonXarelto | $125 | $19,98118 claims |
| Astellas Pharma US IncMyrbetriq | $541 | $19,30716 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $153 | $16,76419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Amarillo
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.